PHATHOM PHARMACEUTICALS, INC. Earnings Per Share (Basic)
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Earnings Per Share (Basic) of -$0.21 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.21.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.37.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-12-31 was $2.71, a 25.86% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.41.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2025 was -$3.03.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2024 was -$5.29.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2023 was -$3.93.
- PHATHOM PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2022 was -$5.05.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.21 10-Q · filed 2026-07-30 | -$0.58 10-Q · filed 2026-07-30 | $1.90 derived: net income ÷ weighted average shares · filed 2026-07-30 | $1.56 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2026-03-31 | -$0.37 10-Q · filed 2026-04-30 | $2.17 derived: net income ÷ weighted average shares · filed 2026-07-30 | $1.83 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.84 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-12-31 | $2.71 derived: net income ÷ weighted average shares · filed 2026-04-07 | $2.31 derived: net income ÷ weighted average shares · filed 2026-04-07 | $1.28 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$3.03 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.41 10-Q · filed 2025-10-30 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$2.76 10-Q · filed 2025-10-30 | $0.82 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-06-30 | -$1.05 10-Q · filed 2026-07-30 | -$2.36 10-Q · filed 2026-07-30 | $1.24 derived: net income ÷ weighted average shares · filed 2026-07-30 | $0.05 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2025-03-31 | -$1.31 10-Q · filed 2026-04-30 | $2.31 derived: net income ÷ weighted average shares · filed 2026-07-30 | $1.15 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-07-30 |
| 2024-12-31 | $3.65 derived: net income ÷ weighted average shares · filed 2026-04-07 | $2.56 derived: net income ÷ weighted average shares · filed 2026-04-07 | $1.27 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$5.29 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.32 10-Q · filed 2025-10-30 | -$2.87 derived: net income ÷ weighted average shares · filed 2025-10-30 | -$4.29 10-Q · filed 2025-10-30 | -$2.31 derived: net income ÷ weighted average shares · filed 2026-04-07 |
| 2024-06-30 | -$1.56 10-Q · filed 2025-08-07 | -$2.98 10-Q · filed 2025-08-07 | -$0.90 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$1.66 derived: net income ÷ weighted average shares · filed 2026-04-07 |
| 2024-03-31 | -$1.42 10-Q · filed 2025-05-01 | $0.67 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-04-07 |
| 2023-12-31 | $2.12 derived: net income ÷ weighted average shares · filed 2026-04-07 | $1.38 derived: net income ÷ weighted average shares · filed 2026-04-07 | $0.69 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$3.93 10-K · filed 2025-03-06 |
| 2023-09-30 | -$0.76 10-Q · filed 2024-11-07 | -$1.60 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.48 10-Q · filed 2024-11-07 | -$3.75 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2023-06-30 | -$0.84 10-Q · filed 2024-08-08 | -$1.73 10-Q · filed 2024-08-08 | -$3.04 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$4.33 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2023-03-31 | -$0.89 10-Q/A · filed 2024-06-14 | -$2.22 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$3.53 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$4.85 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2022-12-31 | -$1.33 derived: net income ÷ weighted average shares · filed 2024-06-14 | -$2.65 derived: net income ÷ weighted average shares · filed 2024-06-14 | -$3.98 derived: net income ÷ weighted average shares · filed 2024-06-14 | -$5.05 10-K/A · filed 2024-06-14 |
| 2022-09-30 | -$1.32 10-Q · filed 2023-11-09 | -$2.65 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$3.72 10-Q · filed 2023-11-09 | -$4.67 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$1.33 10-Q · filed 2023-08-10 | -$2.40 10-Q · filed 2023-08-10 | -$3.35 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$4.34 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-03-31 | -$1.07 10-Q · filed 2023-05-10 | -$2.02 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$3.00 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$4.00 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2021-12-31 | -$0.95 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.93 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.93 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$3.89 10-K · filed 2023-02-28 |
| 2021-09-30 | -$0.98 10-Q/A · filed 2022-11-09 | -$1.98 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$2.94 10-Q/A · filed 2022-11-09 | |
| 2021-06-30 | -$1.00 10-Q · filed 2022-08-02 | -$1.96 10-Q · filed 2022-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |